Regorafenib + Panitumumab for Colorectal Cancers
NCT02199223 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2
Last updated 2016-09-22
Summary
Evaluate the safety of regorafenib and panitumumab
Conditions
- KRAS and NRAS Wild-type Colorectal Cancer
Interventions
- DRUG
-
regorafenib + panitumumab
Sponsors & Collaborators
- lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-06-30
- Primary Completion
- 2016-05-31
- Completion
- 2016-05-31
Countries
- United States
Study Locations
More Related Trials
-
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
NCT06322563 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
NCT03992456 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NCT00891930 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
NCT00111761 ·Status: COMPLETED ·Phase: PHASE2
-
A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
NCT02402036 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
NCT06194877 ·Status: TERMINATED ·Phase: PHASE1
-
Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
NCT04110093 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT02096354 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
NCT02613221 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
NCT06200363 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
NCT01032291 ·Status: TERMINATED ·Phase: PHASE2
-
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer
NCT02619435 ·Status: UNKNOWN ·Phase: PHASE2
-
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
NCT01412957 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC
NCT02835924 ·Status: COMPLETED ·Phase: PHASE2
-
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
NCT02301962 ·Status: UNKNOWN ·Phase: PHASE4
-
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
NCT03263429 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
NCT04294160 ·Status: TERMINATED ·Phase: PHASE1
-
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
NCT03215264 ·Status: COMPLETED ·Phase: PHASE1
-
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
NCT03657641 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC
NCT00475293 ·Status: COMPLETED ·Phase: PHASE2
-
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
NCT04826003 ·Status: COMPLETED ·Phase: PHASE1
-
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
NCT05730673 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT01280643 ·Status: TERMINATED ·Phase: NA
-
A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer
NCT01801904 ·Status: UNKNOWN ·Phase: PHASE2
-
Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer
NCT01791309 ·Status: COMPLETED ·Phase: PHASE1